These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1749742)

  • 1. Antiarrhythmic drug therapy in congestive heart failure. Indications and complications.
    Ravid S
    Postgrad Med; 1991 Dec; 90(8):99-102, 105. PubMed ID: 1749742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine.
    Podrid PJ; Beau SL
    Am J Cardiol; 1990 Feb; 65(8):56D-64D; discussion 68D-71D. PubMed ID: 2407092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular arrhythmias in congestive heart failure.
    Chakko S; de Marchena E; Kessler KM; Myerburg RJ
    Clin Cardiol; 1989 Sep; 12(9):525-30. PubMed ID: 2571440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new antiarrhythmic drugs. How to put them to the best use.
    Anderson JL
    Postgrad Med; 1988 Mar; 83(4):181-93. PubMed ID: 3353335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure.
    Woosley RL
    Am Heart J; 1987 Nov; 114(5):1280-91. PubMed ID: 3314444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of moricizine in patients with congestive heart failure: a summary of the experience in the United States.
    Pratt CM; Podrid P; Greatrix B; Borland RM; Mahler S
    Am Heart J; 1990 Jan; 119(1):1-7. PubMed ID: 1688682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arrhythmias and heart failure].
    Amann FW; Candinas R
    Ther Umsch; 1993 Jun; 50(6):419-24. PubMed ID: 8351673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antiarrhythmic drugs in patients with heart failure: clinical efficacy, hemodynamic results, and relation to survival.
    Wilson JR
    Circulation; 1987 May; 75(5 Pt 2):IV64-73. PubMed ID: 3552304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proarrhythmia, a serious complication of antiarrhythmic drugs.
    Podrid PJ
    Curr Cardiol Rep; 1999 Nov; 1(4):289-96. PubMed ID: 10980856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are antiarrhythmic drugs safe?
    Katritsis D; Camm AJ
    Clin Cardiol; 1990 Jul; 13(7):491-6. PubMed ID: 2194718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of antiarrhythmic agents in heart failure: implications of CAST.
    Gottlieb SS
    Am Heart J; 1989 Nov; 118(5 Pt 1):1074-7. PubMed ID: 2510486
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia.
    Packer M; Gottlieb SS; Kessler PD
    Am J Med; 1986 Apr; 80(4A):23-9. PubMed ID: 2871753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggravation of arrhythmia: a complication of antiarrhythmic drugs.
    Podrid PJ
    J Cardiovasc Electrophysiol; 1993 Jun; 4(3):311-9. PubMed ID: 8269302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flecainide: a new antiarrhythmic drug.
    Mueller RA; Baur HR
    Clin Cardiol; 1986 Jan; 9(1):1-5. PubMed ID: 3510788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer antiarrhythmic drugs.
    Michelson EL; Dreifus LS
    Med Clin North Am; 1988 Mar; 72(2):275-319. PubMed ID: 3279283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk.
    Podrid PJ
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S65-73. PubMed ID: 1723122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.